Market Overview
Leukemia Market is expected to grow at a CAGR 8.9% during the forecast period (2024-2031).
Leukemia is a type of cancer that affects the blood and bone marrow. It originates in the bone marrow and results in an abnormality in leucocytes or white blood cells. In leukemia, the bone marrow starts producing abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work.
Market Summary
| Metrics | Details |
| Market CAGR | 8.9% |
| Segments Covered | By Disease Type, By Treatment Type, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Market Trends
The global leukemia market growth is driven by the increasing geriatric population base and high unmet needs regarding early diagnosis and treatment of leukemia are the key factors driving the market.
The high unmet need for cancer therapy will drive the market growth
The leukemia therapeutics market is mainly driven by high unmet medical need for cancer therapy and rising investment in healthcare sectors. According to the American Cancer Society, in the United States there were approximately 61,780 new cases of leukemia in 2019.
Among them, the number of new cases of acute myeloid leukemia (AML) were around 21,450. AML is thus considered as one of the most common types of leukemia in adults. Hnece the overall statistics shows that there is a huge number of people that are prone to suffer from leukemia, and which may directly impact the growth of the market in the forecast period.
Similarly, introduction of novel therapies with more efficiency & fewer side effects, metabolic inhibitors, and pipeline products awaiting approvals are expected to drive the market over the forecast period. Increasing patient awareness regarding the latest technological advancements in therapies, and benefits such as tolerability, efficacy & safety are the factors expected to contribute the growth of this market. Ongoing research in the field of molecular diagnosis is expected to lead towards availability of efficient treatments for leukemia and expected to further drive the market growth. Rapidly moving healthcare infrastructure, high market penetration rates, and growing awareness levels are the factors promoting the leukemia market growth in the forecast period.
Complications related to chemotherapy is likely to hamper the market growth
Chemotherapy treats acute myeloid lukaemia effectively. But like other treatments, it often causes side effects. The side effects of chemotherapy are different for each person. They depend on the type of cancer, location, drugs and dose, and general health. But because these drugs travel throughout the body, they can affect normal, healthy cells that are fast-growing, too. Damage to healthy cells causes side effects.
COVID-19 Impact Analysis
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the oncologu market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types including acute myeloid luekaemia. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the acute myeloid luekaemia market.
Market Segment Analysis
Chemotherapy segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Chemotherapy has the largest market share in the in 2020. Chemotherapy is the use of anti-cancer drugs that are injected into the vein, under the skin, or into the cerebrospinal fluid. When given into the cerebrospinal fluid, these drugs enter the bloodstream and reach all areas of the body, making this treatment useful for leukemia that spread throughout the body. Chemotherapy is the main treatment for most people with leukemia. Chemotherapy uses potent drugs or chemicals, often in combinations or intervals, to kill or damage cancer cells in the body. According to the American Cancer Society, in 2019, there was around 22,840 death from leukemia in the United States, that has been reported and leading to the overall growth of the market.
Many companies are also focusing on developing breakthrough products for the treatment of Leukemia in order to maintain their competitive advantage and penetrate new regional markets. Chemotherapy is thus considered as the main treatment option for most individuals with Leukemia. Additionally, the increase in funding for companies involved in the research related to leukemia is expected to drive the growth of the market growth.
Market Geographical Share
North America region holds the largest market share of the global leukemia market
North America is expected to dominate the overall leukemia market in the forecast period. High disease awareness, favorable reimbursement policies, high healthcare access, advanced healthcare infrastructure, high disease prevalence, and government initiatives are critical factors for the substantial growth of the market in the region. According to American Cancer Society estimates, there were around 10,920 deaths due to acute myeloid leukemia in the United States in the year 2019. The statistics involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy.
The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of acute myeloid leukemia patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of acute myeloid leukemia in the country is the prime factor responsible for the growth of the market in the country and the reimbursement policies for cataract treatments is driving the revenue generation in the market.
Companies and Competitive Landscape
The leukemia market is moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the leukemia market globally. For instance, in August 2017, Celgene Corporation and Agios Pharmaceuticals, Inc. have received approval for IDHIFA (enasidenib) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2). IDHIFA, is an oral targeted inhibitor of the IDH2 enzyme.
F. Hoffmann-La Roche Ltd
Overview:
F. Hoffmann-La Roche Ltd (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides pharmaceuticals for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions.
Product Portfolio:
Gazyva/Gazyvaro: Gazyva/Gazyvaro is an engineered monoclonal antibody designed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. Gazyva/Gazyvaro is designed to attack and destroy targeted B-cells both directly and together with the body's immune system. Gazyva is marketed as Gazyvaro in the EU and Switzerland. It is currently approved in more than 90 countries in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia, in more than 80 countries in combination with bendamustine for people with certain types of previously treated follicular lymphoma, and in more than 70 countries in combination with chemotherapy.
